Cavinton - instructions for use, dose, side effects, contraindications

Excipients: ascorbic acid 0.5 mg, sodium disulfite 1.0 mg, tartaric acid 10.0 mg, gasoline 10.0 mg, sorbitol 80.0 mg, water for injection up to 1 ml.

Description:

Colorless or slightly greenish transparent solution.

Pharmacotherapeutic group:Cerebral blood flow improver

ATX: & nbsp

N.06.B.X.18 Vinpocetine

Pharmacodynamics:

Improves the metabolism of the brain, increasing the intake of glucose and oxygen by brain tissue. Increases the resistance of neurons to hypoxia; enhancing glucose transport to the brain,through the blood-brain barrier; translates the process of the decay of glucose into an energetically more economical, aerobic pathway; selectively blocks Ca²⁺/ dependent phosphodiesterase (PDE); increases the levels of adenosine monophosphate (AMP) and cyclic guanosine monophosphate (cGMP) of the brain. Increases the concentration of ATP in the brain tissues; enhances the metabolism of noradrenaline and serotonin of the brain; stimulates the ascending branch of the noradrenergic system, has an antioxidant effect.

Reduces platelet aggregation and increased blood viscosity; increases the deforming ability of erythrocytes and blocks the utilization of adenosine by red blood cells; helps to increase the oxygen release of red blood cells. Strengthens the neuroprotective effect of adenosine.

Increases cerebral blood flow; reduces the resistance of cerebral vessels without a significant change in the indices of the systemic circulation (blood pressure, minute volume, heart rate, total peripheral resistance). Not only does it not have the effect of "stealing," but it also increases blood supply, especially in ischemic areas of the brain with low perfusion.

Pharmacokinetics:

The therapeutic concentration in plasma is 10-20 ng / ml. For parenteral administration, the volume of distribution is 5.3 l / kg. The half-life is 4.74-5 hours. Easily penetrates through the histohematological barriers (including the blood-brain barrier). It is excreted with the kidneys and through the gastrointestinal tract in a ratio of 3: 2.

Indications:

Neurology: reduction in the severity of neurological and mental symptoms in various forms of cerebral circulatory insufficiency (ischemic stroke, restorative stage of hemorrhagic stroke, consequences of a stroke, transient ischemic attack, vascular dementia, vertebrobasilar insufficiency, cerebrovascular atherosclerosis, posttraumatic and hypertensive encephalopathy).

Ophthalmology: chronic vascular diseases of the choroid and retina (eg, thrombosis (occlusion) of the central artery or retinal vein).

To treat hearing loss of the perceptive type, Meniere's disease, idiopathic tinnitus.

Contraindications:

The acute phase of hemorrhagic stroke, severe form of coronary heart disease, severe arrhythmias and a known hypersensitivity to vinpocetine.

Pregnancy, lactation.

Children under 18 years (due to insufficient data)

Dosing and Administration:

The drug is intended for intravenous drip infusion, enter slow (the infusion rate should not exceed 80 drops / min)!

It is forbidden to enter intramuscularly and intravenously without dilution!

For the preparation of infusion, physiological saline or solutions containing dextrose (Salsol, Ringer, Rindex, Reomacrodex) can be used. Infusion solution with Cavinton should be used within the first 3 hours after preparation.

The usual initial daily dose: 20 mg (2 amp.) In 500 ml infusion solution. Depending on the tolerability, within 2-3 days the dose can be increased to no more than 1 mg / kg / day. The average duration of treatment is 10-14 days.

The average daily dose at a body weight of 70 kg is 50 mg (5 amp in 500 ml infusion solution).

When liver and kidney disease correction of the dose is not required.

At the end of the course of intravenous therapy it is recommended to continue treatment with Cavinton® forte tablets (1 table 3 times a day) or Cavinton® (2 tablets 3 times a day).

Side effects:

Side effects on the background of the use of the drug were rarely detected.

Co hand of cardio-vascular system: change in ECG (depression ST, lengthening the interval QT); tachycardia, extrasystole, however, the presence of a causal relationship is not proved. in a natural population, these symptoms are observed with the same frequency; change in blood pressure (often decreased), redness of the skin, phlebitis.

From the central nervous system: sleep disturbances (insomnia, increased drowsiness), dizziness, headache, general weakness (these symptoms may be manifestations of the underlying disease).

From the side of the digestive system: dry mouth, nausea, heartburn.

Other: allergic skin reactions; increased sweating.

Overdose:

Treatment for overdose: gastric lavage, reception of activated charcoal, symptomatic therapy.

Interaction:

Interactions are not observed when used simultaneously with β-blockers (chloranolol, pindolol), clopamid, glibenclamide, digoxin, acenocoumarol, or hydrochlorothiazide.

In rare cases, simultaneous use with a-methyl-dopa is accompanied by some strengthening of the hypotensive effect, when using this combination, regular monitoring of blood pressure is necessary.

Despite the lack of data confirming the possibility of interaction, it is recommended to exercise caution when concurrently with the administration of central nervous, antiarrhythmic action.

Concentrate Cavinton ® for the preparation of a solution for infusions and heparin - are chemically incompatible, so they are not allowed to be injected into one infusion mixture, however, anticoagulants and vinpocetine can be treated concurrently.

Cavinton ® concentrate for the preparation of a solution for infusions is incompatible with infusion solutions containing an amino acid, so they can not be used to dilute Cavinton ®.

Special instructions:

Presence of the syndrome of the prolonged interval QT and taking medications that elongate the interval QT, requires periodic ECG monitoring.

Infusion solution Cavinton ® contains sorbitol (160 mg / 2 ml), therefore, in the presence of diabetes, periodic monitoring of blood sugar levels is necessary.

In case of fructose intolerance or a deficiency of fructose 1,6-diphosphatase, vinpocetine should be avoided.

Effect on the ability to drive transp. cf. and fur:Data on the influence of Vinpocetin on the ability to control the car and working mechanisms there.

Form release / dosage:

Concentrate for solution for infusion, 5 mg / ml.

Packaging:

For 2 ml, 5 ml or 10 ml of the drug in ampoules of brown glass I hydrolytic class with a point for the break in white. 5 ampoules in a plastic pallet.

2 ml and 5 ml: 2 plastic pallets in a cardboard box with instructions for use.

10 ml: 1 plastic pallet in a cardboard box with instructions for use.

Storage conditions:

Store in a dark place at a temperature of no higher than 25 ° C.

Keep out of the reach of children.

Shelf life:

5 years.

Do not use after the expiration date printed on the package.

Terms of leave from pharmacies:On prescription

Registration number:П N014725 / 02

Date of registration:18.01.2008 / 08.06.2017

Expiration Date:Unlimited

The owner of the registration certificate:GEDEON RICHTER, OJSC GEDEON RICHTER, OJSC Hungary

Manufacturer: & nbsp

GEDEON RICHTER, Ltd. Hungary

Representation: & nbspGEDEON RICHTER OJSC GEDEON RICHTER OJSC Hungary

Information update date: & nbsp27.11.2017

Illustrated instructions

Instructions

Cavinton® (Cavinton®)